Haemonetics (NYSE:HAE – Get Free Report) announced its quarterly earnings data on Tuesday. The medical instruments supplier reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.32, Briefing.com reports. Haemonetics had a return on equity of 20.13% and a net margin of 9.87%. The business had revenue of […]
Haemonetics (NYSE:HAE – Get Free Report) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $3.60-3.90 mln for the period, compared to the consensus earnings per share estimate of $3.59. The company issued revenue guidance of +6-9% yr/yr to ~$1.24-1.27 billion, compared to the consensus […]
Haemonetics (NYSE:HAE – Get Free Report) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $3.60-$3.90 for the period, compared to the consensus estimate of $3.59. The company issued revenue guidance of $1.24 billion-$1.27 billion, compared to the consensus revenue estimate of $1.24 billion. Haemonetics also updated […]
Robeco Institutional Asset Management B.V. boosted its holdings in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 170.6% during the first quarter, Holdings Channel.com reports. The institutional investor owned 9,200 shares of the medical instruments supplier’s stock after acquiring an additional 5,800 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Haemonetics […]